newsfilter
← Latest News
Business Wire·

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

  • Zura Bio Limited appointed Sandeep Kulkarni, M.D. as Chief Executive Officer effective January 21, 2026.
  • Dr. Kulkarni will continue serving as a Director of the Company while assuming the CEO role.
  • Robert Lisicki resigned as CEO & Director effective January 21, 2026, following a medical leave of absence.
  • Kim Davis succeeded Lisicki as Interim CEO since October 2025 & will retain her roles as Chief Operating Officer, Chief Legal Officer, & Corporate Secretary.
  • Dr. Kulkarni previously served as co-founder & CEO of Tourmaline Bio until its acquisition by Novartis in October 2025.
  • The Company anticipates two potentially transformative clinical readouts for its lead program, tibulizumab, within the next 18 months.
  • Tibulizumab is an in-class bispecific antibody targeting IL-17 & BAFF pathways, currently evaluated in Phase 2 studies for hidradenitis suppurativa (TibuSHIELD) & systemic sclerosis (TibuSURE).
  • Additional candidates crebankitug (ZB-168) & torudokimab (ZB-880) have completed Phase 1/1b studies & are being evaluated for autoimmune conditions.
  • Dr. Kulkarni has served on Zura's Board since the March 2023 listing & previously held leadership roles at Immunovant, KVP Capital, Roivant Sciences, & The Boston Consulting Group.